A number of other analysts have also recently weighed in on STAA. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of STAAR Surgical Company in a research note to investors on Thursday, May 3rd.
STAAR Surgical Company traded up 1.10% on Monday, hitting $9.8475. STAAR Surgical Company has a 52-week low of $4.48 and a 52-week high of $11.79. The company has a market cap of $358.8 million and a price-to-earnings ratio of 270.56.
STAAR Surgical Company last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.04 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.03 by $0.01. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Analysts expect that STAAR Surgical Company will post $0.02 EPS next quarter.
STAAR Surgical Company (STAAR) is engaged in developing, producing, and marketing intraocular lenses (IOLs) and other products for minimally invasive ophthalmic surgery.